671 results on '"Witzig TE"'
Search Results
2. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia
3. Effect of complete response on outcome following autologous stem cell transplantation for myeloma
4. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma
5. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma
6. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone
7. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma
8. Autologous stem cell transplantation for relapsed and primary refractory myeloma
9. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
10. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma
11. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
12. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma
13. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation
14. Thalidomide for previously untreated indolent or smoldering multiple myeloma
15. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease
16. A366 Relevance of Conventional Prognostic Factors in Multiple Myeloma (MM) in the Era of Novel Therapies
17. A481 Long-Term Results of Single-Agent Thalidomide as Initial Therapy for Smoldering or Indolent Myeloma
18. A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenström Macroglobulinemia, the DFCI Experience
19. B539 Proteomic Analysis of Multiple Myeloma Identifies Upregulation of the Novel Protein CRIK
20. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
21. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
22. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases [see comments]
23. Chronic natural killer cell lymphocytosis: a descriptive clinical study
24. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
25. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
26. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.
27. Weight-based dosing of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
28. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
29. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
30. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy.
31. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
32. Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinoma
33. Building on the promise of radioimmunotherapy.
34. Review of 1027 patients with newly diagnosed multiple myeloma.
35. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
36. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
37. Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma.
38. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma.
39. Clinical course of patients with relapsed multiple myeloma.
40. Therapeutic options in patients with lymphoma and severe liver dysfunction.
41. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
42. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
43. Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma
44. Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia.
45. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.
46. Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
47. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori ?
48. Defining primary refractory large B-cell lymphoma.
49. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL.
50. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.